泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301263 泰恩康

已收盘 08-13 15:00:00

{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":36.26,"timestamp":1755068637000,"preClose":35.98,"halted":0,"volume":5883900,"delay":0,"changeRate":0.0078,"floatShares":304000000,"shares":425000000,"eps":0.2217,"marketStatus":"已收盘","change":0.28,"latestTime":"08-13 15:00:00","open":35.99,"high":36.5,"low":35.5,"amount":212000000,"amplitude":0.0278,"askPrice":36.26,"askSize":25,"bidPrice":36.25,"bidSize":72,"shortable":0,"etf":0,"ttmEps":0.2217,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755135000000},"marketStatusCode":5,"adr":0,"adjPreClose":35.98,"symbolType":"stock","openAndCloseTimeList":[[1755048600000,1755055800000],[1755061200000,1755068400000]],"highLimit":39.58,"lowLimit":32.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"isCdr":false,"pbRate":8.51,"roa":"--","peRate":163.554353,"roe":"1.77%","epsLYR":0.26,"committee":-0.819172,"marketValue":15429000000,"turnoverRate":0.0194,"status":0,"floatMarketCap":11008000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2558610001","title":"泰恩康：CKBA作为全球创新小分子药物优势解析","url":"https://stock-news.laohu8.com/highlight/detail?id=2558610001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558610001?lang=zh_cn&edition=full","pubTime":"2025-08-12 17:00","pubTimestamp":1754989248,"startTime":"0","endTime":"0","summary":"CKBA在安全性方面具有明显优势，II期临床试验中未发生与试验用药品相关的严重不良事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081200028434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"1191021215","title":"这个赛道，火爆！机构密集调研+资金大幅加仓，仅13股","url":"https://stock-news.laohu8.com/highlight/detail?id=1191021215","media":"数据宝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191021215?lang=zh_cn&edition=full","pubTime":"2025-08-11 07:42","pubTimestamp":1754869344,"startTime":"0","endTime":"0","summary":"创新药市场规模不断扩大，并有望迎来量价齐升的黄金期。从全球来看，创新药物的研发突破离不开政策及资金支持。可见，创新药公司研发强度大幅超越医药生物行业整体水平。多家药企披露新药研发进展今年以来，投资者对创新药的关注度大幅提升。从市场表现来看，创新药行情于5月份开始启动，这些披露创新药进展公司自5月1日以来平","market":"sh","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301263","688062","688235"],"gpt_icon":0},{"id":"2557669133","title":"8月5日泰恩康跌6.34%，鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557669133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557669133?lang=zh_cn&edition=full","pubTime":"2025-08-05 16:18","pubTimestamp":1754381884,"startTime":"0","endTime":"0","summary":"证券之星消息，8月5日泰恩康跌6.34%，收盘报37.65元，换手率5.55%，成交量16.86万手，成交额6.51亿元。重仓泰恩康的前十大公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为鹏华基金的鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为10.17亿元，最新净值0.9343，较上一交易日上涨1.39%，近一年上涨68.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500026647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2557365961","title":"泰恩康：承办创新免疫治疗临床转化研究高峰论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=2557365961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557365961?lang=zh_cn&edition=full","pubTime":"2025-08-05 15:45","pubTimestamp":1754379911,"startTime":"0","endTime":"0","summary":"投资者提问：尊敬的董秘，请问贵司是否在2025年8月8日（周五）13:30 至 18:00地点: 汕头国际会展中心，地址为广东省汕头市澄海区东海岸大道191号主题: 权威专家将共同探讨CKBA新靶点、新机制、白癜风II期临床结果、玫瑰痤疮II/III期临床方案以及在阿尔兹海默症领域的拓展2泰恩康回复：投资者您好，公司作为“2025届汕头大健康产业创新发展大会暨健康产品博览会”的承办单位之一，负责举办分论坛“创新免疫治疗临床转化研究高峰论坛”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500022483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2556866033","title":"泰恩康(301263.SZ)拟推2025年员工持股计划 持股规模不超497.51万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2556866033","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556866033?lang=zh_cn&edition=full","pubTime":"2025-08-04 19:31","pubTimestamp":1754307069,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)披露2025年员工持股计划(草案)，持股计划初始设立时总人数不超过150人，其中董事(不含独立董事)、监事、高级管理人员7人，其他员工不超过143人。员工持股计划股票来源为拟通过二级市场购买等法律法规许可的方式获得泰恩康A股，持股规模不超过497.51万股;员工持股计划拟筹集资金总额上限为2亿元。本员工持股计划的存续期为36个月，所获标的股票的锁定期为12个月，自本员工持股计划草案经公司股东大会审议通过且公司公告最后一笔标的股票购买完成之日起计算。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2556806912","title":"泰恩康(301263.SZ)子公司CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2556806912","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556806912?lang=zh_cn&edition=full","pubTime":"2025-08-04 15:53","pubTimestamp":1754294025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康 发布公告，近日，公司控股子公司江苏博创园生物医药科技有限公司自主研发的1类创新药CKBA软膏白癜风适应症II期临床试验已于近日完成数据整理并揭盲。此次CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标，进一步验证了CKBA作为首个靶向T细胞脂肪酸代谢通路的FIC创新小分子药物在自身免疫性疾病领域的巨大开发潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2556806948","title":"泰恩康：CKBA软膏白癜风适应症II期临床试验结果达到预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2556806948","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556806948?lang=zh_cn&edition=full","pubTime":"2025-08-04 15:49","pubTimestamp":1754293798,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0250","301263","III","06978","159992","BK1574","BK4134","BK1161"],"gpt_icon":0},{"id":"2556898050","title":"8月1日泰恩康涨5.98%，鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2556898050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556898050?lang=zh_cn&edition=full","pubTime":"2025-08-01 16:20","pubTimestamp":1754036440,"startTime":"0","endTime":"0","summary":"证券之星消息，8月1日泰恩康涨5.98%，收盘报39.15元，换手率5.21%，成交量15.8万手，成交额6.1亿元。重仓泰恩康的前十大公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为鹏华基金的鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为10.17亿元，最新净值0.9205，较上一交易日上涨0.1%，近一年上涨58.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100026976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2555039657","title":"7月29日泰恩康现500.03万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2555039657","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555039657?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:05","pubTimestamp":1753779950,"startTime":"0","endTime":"0","summary":"证券之星消息，7月29日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格33.9元，相对当日收盘价折价9.89%，成交14.75万股，成交金额500.03万元，买方营业部为平安证券股份有限公司河南分公司，卖方营业部为中信证券股份有限公司上海世博馆路证券营业部。近三个月该股共发生1笔大宗交易，合计成交1475.0手，折价成交1笔。截至2025年7月29日收盘，泰恩康报收于37.62元，下跌0.37%，换手率3.42%，成交量10.37万手，成交额3.91亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900028223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2553821858","title":"7月23日泰恩康跌7.77%，鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553821858","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553821858?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:32","pubTimestamp":1753259532,"startTime":"0","endTime":"0","summary":"证券之星消息，7月23日泰恩康跌7.77%，收盘报35.73元，换手率5.88%，成交量17.84万手，成交额6.56亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为鹏华基金的鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为10.17亿元，最新净值0.8988，较上一交易日下跌0.16%，近一年上涨54.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300027326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2552646641","title":"泰恩康最新公告：控股子公司CKBA乳膏玫瑰痤疮适应症申报新药临床试验取得受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2552646641","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552646641?lang=zh_cn&edition=full","pubTime":"2025-07-18 17:40","pubTimestamp":1752831614,"startTime":"0","endTime":"0","summary":"泰恩康公告称，公司控股子公司博创园收到国家药品监督管理局签发的受理通知书，同意受理博创园提交的CKBA乳膏玫瑰痤疮适应症开展II/III期无缝适应性临床试验申请。CKBA乳膏是一种以中药乳香活性成分为先导化合物进行结构修饰优化而获得的小分子药物，具有全新结构、拥有自主知识产权、作用机制明确、安全性良好特点。截至目前，国内尚未有治疗玫瑰痤疮的1类创新药获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800028367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK0250","BK1583","301263","BK1141","BK1576"],"gpt_icon":0},{"id":"2552746542","title":"泰恩康：公司主要的医药自主研发项目42项","url":"https://stock-news.laohu8.com/highlight/detail?id=2552746542","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552746542?lang=zh_cn&edition=full","pubTime":"2025-07-18 17:06","pubTimestamp":1752829567,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)07月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问贵公司自主研发项目大概有多少？审批进展顺利吗？泰恩康回复：投资者您好，截至目前，公司主要的医药自主研发项目42项，涵盖了多个治疗领域，部分核心研发药品市场空间巨大，其中21项药品注册批件申请已获受理，形成了良好的研发梯队。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800027016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0250","BK1161","09939","159938","BK1574","301263"],"gpt_icon":0},{"id":"2552646560","title":"泰恩康：CKBA软膏白癜风2期临床结果预计7月底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2552646560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552646560?lang=zh_cn&edition=full","pubTime":"2025-07-18 17:00","pubTimestamp":1752829249,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)07月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问下CKBA白癜风2期临床结果大概具体什么时间出？CKBA还会往那些方面拓展？泰恩康回复：您好，CKBA软膏白癜风适应症II期临床试验在今年4月底已完成全部受试者的用药，预计将于今年7月底公布II期临床试验结果。后续在CKBA的靶点作用机制有效性得到进一步验证后，公司将积极拓展其他适应症。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800026753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2551418239","title":"医药生物：创新药及CXO继续爆发 关注玫瑰痤疮新药(泰恩康/科笛)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551418239","media":"华福证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551418239?lang=zh_cn&edition=full","pubTime":"2025-07-13 00:00","pubTimestamp":1752336000,"startTime":"0","endTime":"0","summary":"玫瑰痤疮百亿级潜在蓝海，关注泰恩康：中国玫瑰痤疮患者或达5000 万人，女性为主，自带医美属性。当前玫瑰痤疮治疗手段有限，获批药物如甲硝唑凝胶、过氧化苯甲酰、米诺环素等多为老药新用，普遍存在皮肤干燥、红斑、烧灼感等副作用，亟待有安全性及有效性均好的药物上市。经过我们测算，中国玫瑰痤疮创新药潜在市场空间或超百亿元。本周建议关注组合：信达生物、康方生物、中国生物制药、云顶新耀、海正药业、泰恩康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713185619a6a6a7c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713185619a6a6a7c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","163118","301263","01177","BK0028","BK0188","159992","BK0250","09926","000808.SH","BK0060","600267","01801"],"gpt_icon":0},{"id":"2549833546","title":"泰恩康最新公告：全资子公司收到药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2549833546","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549833546?lang=zh_cn&edition=full","pubTime":"2025-07-08 18:31","pubTimestamp":1751970666,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称，公司全资子公司华铂凯盛近日收到国家药监局签发的盐酸毛果芸香碱滴眼液境内生产药品注册上市许可申请《受理通知书》。该药品为化学药品3类，规格为1.25%（2.5ml：31.25mg），申请人为华铂凯盛。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800032187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2549567184","title":"泰恩康上涨5.2%，报40.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567184","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567184?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:41","pubTimestamp":1751938873,"startTime":"0","endTime":"0","summary":"7月8日，泰恩康盘中上涨5.2%，截至09:41，报40.7元/股，成交1.52亿元，换手率1.26%，总市值173.18亿元。截至5月30日，泰恩康股东户数9998，人均流通股3.04万股。2025年1月-3月，泰恩康实现营业收入1.85亿元，同比减少2.35%；归属净利润3154.6万元，同比减少30.62%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/08094151545120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2547065043","title":"泰恩康：布局老年慢性病领域药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2547065043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547065043?lang=zh_cn&edition=full","pubTime":"2025-06-30 16:39","pubTimestamp":1751272761,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康06月30日在投资者关系平台上答复投资者关心的问题。泰恩康回复：您好，公司在老年慢性病领域还布局了治疗前列腺增生的非那雄胺他达拉非胶囊、治疗帕金森病的盐酸普拉克索缓释片、治疗骨质疏松的阿仑膦酸钠片等，具体请查阅公司披露的《2024年年度报告》中的第三节“管理层讨论与分析”章节中的“研发投入”相关具体内容，感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000021437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2545940438","title":"泰恩康：CKBA软膏白癜风适应症II期临床试验预计7月底公布结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2545940438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545940438?lang=zh_cn&edition=full","pubTime":"2025-06-24 16:51","pubTimestamp":1750755079,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问下CKBA白癜风2期临床结果大概具体什么时间出？能否早日与投资者分享？CKBA还会往那些方面拓展？NKBA目前有哪些进展？谢谢泰恩康回复：您好，CKBA软膏白癜风适应症II期临床试验在今年4月底已完成全部受试者的用药，预计将于今年7月底公布II期临床试验结果。后续在CKBA的靶点作用机制有效性得到进一步验证后，公司将积极拓展其他适应症。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400027078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","03347","BK1141","BK0250","BK1583","301263"],"gpt_icon":0},{"id":"2544125373","title":"6月20日泰恩康发布公告，股东减持569.43万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544125373","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544125373?lang=zh_cn&edition=full","pubTime":"2025-06-20 18:01","pubTimestamp":1750413700,"startTime":"0","endTime":"0","summary":"证券之星消息，6月20日泰恩康发布公告《泰恩康:关于2024年员工持股计划减持完毕的公告》，其股东广东泰恩康医药股份有限公司2024年员工持股计划于2025年6月4日至2025年6月20日间合计减持569.43万股，占公司目前总股本的1.3383%，变动期间该股股价上涨7.26%，截止6月19日收盘报32.96元。股东增减持详情见下表：根据泰恩康2025年一季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000027527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2544514793","title":"泰恩康(301263.SZ)：硫酸氨基葡萄糖胶囊注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2544514793","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544514793?lang=zh_cn&edition=full","pubTime":"2025-06-20 17:10","pubTimestamp":1750410617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的硫酸氨基葡萄糖胶囊境内生产药品注册上市许可申请《受理通知书》，国家药监局对上述药品的药品注册上市许可申请进行了审查，决定予以受理。硫酸氨基葡萄糖胶囊适用于原发性及继发性骨关节炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755124973978,"stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.1091},{"period":"3month","weight":0.558},{"period":"6month","weight":1.1969},{"period":"1year","weight":1.6361},{"period":"ytd","weight":1.4373}],"compareEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.0465},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.1006},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.099}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"16342人(较上一季度增加63.45%)","perCapita":"18577股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"42549万元","survey":"　　广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}